<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023811</url>
  </required_header>
  <id_info>
    <org_study_id>RIST4721-104</org_study_id>
    <nct_id>NCT05023811</nct_id>
  </id_info>
  <brief_title>A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristea Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristea Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of&#xD;
      [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2, 2021</start_date>
  <completion_date type="Anticipated">September 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in all excreta: CumAe</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in all excreta: Cum%Ae</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of routes and rates of elimination of [14C]RIST4721 by Ae</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of routes and rates of elimination of [14C]RIST4721 by %Ae</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of routes and rates of elimination of [14C]RIST4721 by CumAe</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of routes and rates of elimination of [14C]RIST4721 by Cum%Ae by interval</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of plasma, urine and fecal samples for metabolite profiling</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of plasma, urine and fecal samples for structural identification</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of plasma, urine and fecal samples for quantification analysis</measure>
    <time_frame>Day 1 to Day 17</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <condition>ADME</condition>
  <arm_group>
    <arm_group_label>[14C]RIST4721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]RIST4721 oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]RIST4271</intervention_name>
    <description>[14C]RIST4271 oral solution</description>
    <arm_group_label>[14C]RIST4721</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Body mass index (BMI) 18.0 to 30.0 kg/m2 as measured at screening&#xD;
&#xD;
          -  Weight ≥50 kg and ≤100 kg inclusive at screening&#xD;
&#xD;
          -  Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per&#xD;
             day)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Evidence of current SARS-CoV-2 infection&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 2017, shall participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aristea Therapeutics</last_name>
    <phone>858-465-6142</phone>
    <email>info@aristeatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences Ltd</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharan Sidhu, MD</last_name>
      <phone>44 (0)115 974 9000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

